- Home
- ACXP vs RNXT Comparison
ACXP vs RNXT Comparison
Compare ACXP & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACXP
- RNXT
- Stock Information
- Founded
- ACXP 2017
- RNXT 2012
- Country
- ACXP United States
- RNXT United States
- Employees
- ACXP N/A
- RNXT N/A
- Industry
- ACXP Biotechnology: Pharmaceutical Preparations
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- ACXP Health Care
- RNXT Health Care
- Exchange
- ACXP Nasdaq
- RNXT Nasdaq
- Market Cap
- ACXP 8.4M
- RNXT 44.6M
- IPO Year
- ACXP 2021
- RNXT 2021
- Fundamental
- Price
- ACXP $0.47
- RNXT $1.30
- Analyst Decision
- ACXP Strong Buy
- RNXT Strong Buy
- Analyst Count
- ACXP 2
- RNXT 2
- Target Price
- ACXP $10.00
- RNXT $7.25
- AVG Volume (30 Days)
- ACXP 18.7M
- RNXT 135.9K
- Earning Date
- ACXP 08-08-2025
- RNXT 08-12-2025
- Dividend Yield
- ACXP N/A
- RNXT N/A
- EPS Growth
- ACXP N/A
- RNXT N/A
- EPS
- ACXP N/A
- RNXT N/A
- Revenue
- ACXP N/A
- RNXT $240,000.00
- Revenue This Year
- ACXP N/A
- RNXT $3,104.65
- Revenue Next Year
- ACXP N/A
- RNXT $301.89
- P/E Ratio
- ACXP N/A
- RNXT N/A
- Revenue Growth
- ACXP N/A
- RNXT N/A
- 52 Week Low
- ACXP $0.30
- RNXT $0.75
- 52 Week High
- ACXP $3.33
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- ACXP 52.38
- RNXT 53.41
- Support Level
- ACXP $0.45
- RNXT $1.29
- Resistance Level
- ACXP $0.59
- RNXT $1.38
- Average True Range (ATR)
- ACXP 0.08
- RNXT 0.07
- MACD
- ACXP -0.01
- RNXT -0.01
- Stochastic Oscillator
- ACXP 27.06
- RNXT 48.39
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.